Neopharmed Gentili S.P.A. successfully completes the placement of its €890 million senior secured floating rate notes due 2033


Milan, June 18, 2026 – Neopharmed Gentili S.p.A., a joint stock company (società per azioni) incorporated under the laws of Italy (the “Issuer” or “Neopharmed”), has successfully completed today the placement on the high-yield bond market (the “Offering”) of €890.0 million of Senior Secured Floating Rate Notes due 2033 (the “Notes”). The issuance was upsized from an initial Offering size of €425.0 million in light of strong demand from investors and favorable market conditions.

The proceeds of the Offering will be used (i) to redeem in full the €400.0 million Senior Secured Floating Rate Notes due 2030 (the “Existing Floating Rate Notes”) and the €450.0 million Senior Secured Fixed Rate Notes due 2030 (the “Existing Fixed Rate Notes”), both issued by the Issuer on April 8, 2024, including redemption premium and accrued and unpaid interest thereon, (ii) to make a distribution to the parent of the Issuer in an amount of approximately €23.0 million to repay a portion of the Senior Secured Floating Rate Payment-In-Kind Notes due 2031 issued by the parent of the Issuer on September 29, 2025, and (iii) to pay fees and expenses incurred in connection with the Offering.

The Notes will be issued at an issue price of 100.000% and will bear interest at a rate equal to three-month EURIBOR (subject to a 0% floor) plus 3.250% per annum, reset quarterly.

The issuance and settlement of the Notes is expected to occur on June 29, 2026, subject to customary closing conditions.

Application has been made for the Notes to be listed on the Official List of the Luxembourg Stock Exchange and admitted to trading on the Euro MTF market thereof.

A conditional notice of redemption was sent to the noteholders of each of the Existing Floating Rate Notes and the Existing Fixed Rate Notes today.